Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Berk

Showing results (311-320 of 398) with videos related to

Pageof 40
Sort By:
Journal of Hepatology|March 1, 1992
Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trialL Berk, S W Schalm, R A de Man, et al.
Journal of Affective Disorders|March 22, 2015
Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectivenessG Murray, N D Leitan, M Berk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 27, 2022
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experienceOmar K Siddiqi, Yuliya Y Mints, John L Berk, et al.
Journal of the Neurological Sciences|July 12, 2014
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trialsN Suanprasert, J L Berk, M D Benson, et al.
JAMA Cardiology|February 15, 2017
Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction ModelMarios Arvanitis, Clarissa M Koch, Gloria G Chan, et al.
JMIR Cancer|December 12, 2023
Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App Into Care of Patients With Cancer: Qualitative Study of Patient and Provider PerspectivesMegan E Gregory, Weidan Cao, Saurabh Rahurkar, et al.
British Journal of Haematology|March 23, 1999
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo, V Sanchorawala, C Fisher, et al.
Journal of the American College of Cardiology|November 28, 2015
Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisMorie A Gertz, Merrill D Benson, Peter J Dyck, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 25, 2020
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patientsOrly Moshe-Lilie, Diana Dimitrova, Stephen B Heitner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2018
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid diseaseElena S Klimtchuk, Tatiana Prokaeva, Nicholas M Frame, et al.
Pageof 40

Showing results (311-320 of 398) with videos related to

Sort By:
Pageof 40
Journal of Hepatology|March 1, 1992
Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trialL Berk, S W Schalm, R A de Man, et al.
Journal of Affective Disorders|March 22, 2015
Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectivenessG Murray, N D Leitan, M Berk, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 27, 2022
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experienceOmar K Siddiqi, Yuliya Y Mints, John L Berk, et al.
Journal of the Neurological Sciences|July 12, 2014
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trialsN Suanprasert, J L Berk, M D Benson, et al.
JAMA Cardiology|February 15, 2017
Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction ModelMarios Arvanitis, Clarissa M Koch, Gloria G Chan, et al.
JMIR Cancer|December 12, 2023
Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App Into Care of Patients With Cancer: Qualitative Study of Patient and Provider PerspectivesMegan E Gregory, Weidan Cao, Saurabh Rahurkar, et al.
British Journal of Haematology|March 23, 1999
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo, V Sanchorawala, C Fisher, et al.
Journal of the American College of Cardiology|November 28, 2015
Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisMorie A Gertz, Merrill D Benson, Peter J Dyck, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 25, 2020
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patientsOrly Moshe-Lilie, Diana Dimitrova, Stephen B Heitner, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2018
Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid diseaseElena S Klimtchuk, Tatiana Prokaeva, Nicholas M Frame, et al.
Pageof 40